Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone (GHRH) that prompts the pituitary to release the body’s own growth hormone in natural pulses.
Rather than supplying growth hormone directly, tesamorelin is a GHRH analogue: it signals the pituitary gland to produce and release your own growth hormone, preserving the body’s natural pulsatile rhythm. It belongs to the class we set out at growth hormone peptides.
It has been studied most for the reduction of excess visceral fat, the deep abdominal fat around the organs. Tesamorelin is the active ingredient in Egrifta, approved by the FDA for HIV-associated lipodystrophy; it holds no EU marketing authorisation. How it compares with the other GHRH analogue we supply is at tesamorelin vs CJC-1295.
What we supply is TESAMORELIN 32: 32 mg of tesamorelin already in solution in a 3 ml pre-loaded multi-dose pen, tested per batch by an independent laboratory for identity, purity and sterility, and shipped cold-chain. The certificate for your batch is reachable from the QR code on the pen or from the certificate index.
Tesamorelin was assessed in randomised, placebo-controlled human trials for visceral adipose tissue (VAT) reduction, which supported its regulatory approval.
Trial and approval details describe the pharmaceutical compound in its studied indication; they are not a claim about this product.
An independent laboratory tests every batch for identity, purity and sterility, and the certificate of analysis is published for download.
The pen ships ready to use. No reconstitution, no measuring, no vials.
Insulated packaging with a cooling element and a temperature indicator. Orders placed before 12:00 on a business day dispatch the same day.
Scan the QR code on your pen, or open the certificate index, to see the exact certificate for your lot.
No. It is a GHRH analogue that prompts your body to release its own growth hormone, rather than adding synthetic growth hormone.
Mainly for the reduction of visceral abdominal fat. It is FDA-approved for HIV-associated lipodystrophy under the name Egrifta, and that trial population is the one its evidence describes.
Yes. Each batch is tested by an independent laboratory, and the certificate is one QR scan away on the pen, or downloadable from the product page and the certificate index.
A 32 mg pre-loaded pen with its batch certificate, shipped cold-chain across Europe.
Check eligibilitySupplied for research and analytical purposes only. Not a medicine, not for human consumption, and not intended to diagnose, treat, cure or prevent any disease.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy